Novartis and Eli Lilly end litigation over psoriasis drug that drew European antitrust scrutiny (update*)
Novartis and Eli Lilly have settled a patent dispute that drew antitrust scrutiny from Swiss and EU regulators in September over allegations that Novartis was engaging in abusive litigation to stymie...To view the full article, register now.
Already a subscriber? Click here to view full article